Osaic Holdings
CTKB icon

Osaic Holdings’s Cytek Biosciences CTKB Stock Holding History

Osaic Holdings’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$819 Sell
185
-957
-84% -$4.08K ﹤0.01% 7541
2026
Q1 		$4.99K Buy
1,142
+1,025
+876% +$4.84K ﹤0.01% 6686
2025
Q4 		$591 Buy
117
+97
+485% +$450 ﹤0.01% 7410
2025
Q3 		$82 Hold
20
– – ﹤0.01% 7761
2025
Q2 		$68 Hold
20
– – ﹤0.01% 7593
2025
Q1 		$80 Sell
20
-27
-57% -$140 ﹤0.01% 7255
2024
Q4 		$305 Hold
47
– – ﹤0.01% 7119
2024
Q3 		$260 Sell
47
-42
-47% -$238 ﹤0.01% 7135
2024
Q2 		$497 Buy
+89
New +$535 ﹤0.01% 6982
2023
Q3 		– Sell
-20
Closed -$171 – 7419
2023
Q2 		$171 Sell
20
-80
-80% -$718 ﹤0.01% 7230
2023
Q1 		$918 Sell
100
-347
-78% -$3.73K ﹤0.01% 6983
2022
Q4 		$4K Buy
447
+427
+2,135% +$5.74K ﹤0.01% 6378
2022
Q3 		$0 Hold
20
– – ﹤0.01% 7291
2022
Q2 		$0 Buy
+20
New +$199 ﹤0.01% 7383

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Osaic Holdings's CTKB Position: Q2 2026 in Review

Osaic Holdings reduced its Cytek Biosciences (CTKB) stake by 84% in Q2 2026, selling an estimated $4.08K and leaving 185 shares worth $819. The position accounts for ﹤0.01% of the portfolio, ranked #7541.

Osaic Holdings first reported a position in CTKB in Q2 2022 and has held it in 14 quarters since. The position peaked at $4.99K in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Osaic Holdings held 185 shares of Cytek Biosciences worth $819 as of Q2 2026.
  • Osaic Holdings sold 957 Cytek Biosciences shares in Q2 2026, an estimated $4.08K.
  • Cytek Biosciences made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7541 holding.
  • Osaic Holdings first reported a position in Cytek Biosciences in Q2 2022 and has held it in 14 quarters since.
  • Osaic Holdings's Cytek Biosciences position peaked at $4.99K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.